Acta Medica Okayama volume72 issue3
2018-06 発行
Miyata, Yasuhiko
Department of Hematology, Nagoya Medical Center
Saito M. , Akiko
Clinical Research Center, Nagoya Medical Center
Yano, Takahiro
Department of Hematology, Tokyo Medical Center
Yoshida, Isao
Department of Hemato-oncology, Shikoku Cancer Center
Suehiro, Youko
Department of Hematology, Kyushu Cancer Center
Harada, Naoki
Department of Hematology, Kyushu Medical Center
Nagai, Hirokazu
Department of Hematology, Nagoya Medical Center
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
rituximab
diffuse large B-cell lymphoma
open-label
single arm trial